CD30.CAR-EBVSTs for Relapsed or Refractory CD30-Positive Lymphomas
This study is testing a new cell therapy called CD30.CAR-EBVST cells for people aged 12 to 75 with certain types of lymphoma (a cancer of the immune system) that have returned or not responded to previous treatments. These lymphomas include Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, and anaplastic T cell lymphoma. To join, your tumor must be CD30-positive, which means it has a specific marker on its cells. The CD30.CAR-EBVST cells are made from healthy donor blood and are designed to target and fight your cancer cells. The main goal of this study is to find a safe dose of these cells by carefully increasing the dose for groups of patients. We don't know the best dose yet, but we are looking for a dose that is both effective and has manageable side effects. This study is currently recruiting up to 18 participants.
- Study design
- This is an interventional study where participants receive a single infusion of CD30.CAR-EBVST cells. It is a dose-escalation study, meaning initial patients receive lower doses, and later groups may receive higher doses if the lower doses are safe.
- What's involved
- You will need to have recovered from previous chemotherapy side effects and not be taking other experimental treatments. The study involves specific visits and procedures, but the record does not detail their frequency or duration.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, dose-limiting toxicity, is measured at 28 days after treatment.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
At a glance
Conditions
Where it's being run
2 sites across 1 statesStudy leadership
- Carlos Ramos, MD · PRINCIPAL_INVESTIGATOR · Baylor College of Medicine
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Dose limiting toxicity rate (DLT) by CTCAE 5.028 days
Any Grade 5 event, / Non-hematologic dose-limiting toxicity is any Grade 3 or Grade 4 non-hematologic toxicity that affects the cardiopulmonary system, or corresponds to neurotoxicity, or otherwise fails to return to Grade 2 within 72 hours, / Grade 2-4 allergic reaction to T-Cells, / Grade 3-4 GVHD, / Hematologic dose limiting toxicity is defined as any Grade 4 hematologic toxicity that fails to return to Grade 2 or baseline (whichever is more severe) within 14 days or within 28 days for patients with evidence of bone marrow disease.